Research programme: peptide therapeutics - Soricimed

Drug Profile

Research programme: peptide therapeutics - Soricimed

Alternative Names: SOR-C27; SOR-N54; Soricidin-derived C-series peptide therapeutics; Soricidin-derived N-series peptide therapeutics

Latest Information Update: 29 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Soricimed Biopharma
  • Class Drug conjugates; Non-opioid analgesics; Peptides
  • Mechanism of Action Apoptosis stimulants; Sodium channel antagonists; TRPV6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Ovarian cancer; Pain; Prostate cancer

Most Recent Events

  • 15 Oct 2013 Pharmacodynamics data from a preclinical trial in Breast and Ovarian cancer released by Soricimed
  • 16 Aug 2012 Preclinical development is ongoing in Canada
  • 25 Oct 2011 Soricimed Biopharma licenses peptide technology from University Health Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top